Blood Cell Count Ratios Predict Immune-related Adverse Events in Metastatic Renal Cell Carcinoma Treated With First-Line Immune Checkpoint Inhibitors

Abstract Background First-line ICI-based therapies are commonplace in mRCC and frequency of irAEs is high. Although prognostication based on irAEs has been demonstrated, prediction of irAE occurrence in mRCC remains a challenge. Early identification of high-risk patients would enable personalized monitoring, earlier detection of irAEs, and more proactive toxicity management. We investigated the role of baseline blood cell count ratios to predict grade ≥2 irAEs with first-line ICI-based therapies in mRCC. Patients and Methods We used the City of Hope national database to retrospectively identify mRCC patients treated with first-line ICI-based therapies from September 2015 to September 2025. Baseline patient demographics and first-line ICI-based regimen were collected. We stratified baseline blood cell ratios: neutrophil-to-eosinophil ratio (NER), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and systemic immune inflammation index (SII) using recursive partitioning and evaluated their association with occurrence of grade ≥2 irAEs. Results A total of 198 patients with mRCC were treated with first-line ICI-based therapy, of which 5 were excluded due to insufficient data. Of the 193 evaluable patients, the median age was 64, 100 patients (51.8%) received ICI-ICI and 93 patients (48.2%) received ICI-TKI. Grade ≥2 irAEs were observed in 57 patients (29.5%) and the most common was ALT/AST elevations in 18 patients (9.3%). All baseline blood cell ratios predicted occurrence of grade ≥2 irAEs in separate multivariable logistic regression analyses for each marker, with SII and PLR emerging as subgroup-specific risk factors in the ICI-ICI and ICI-TKI cohorts, respectively. Conclusion Our findings support a novel role for these baseline blood cell ratios as factors associated with grade ≥2 irAEs in mRCC. These findings are hypothesis-generating and warrant prospective validation in larger patient populations.

Authors

Institutions

Publication Details

Journal
The Oncologist
Published
2026-11-14
DOI
https://doi.org/10.1093/oncolo/oyag454
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Blood Cell Count Ratios Predict Immune-related Adverse Events in Metastatic Renal Cell Carcinoma Treated With First-Line Immune Checkpoint Inhibitors

Miguel Zugman, Tanya Dorff, Sumanta Kumar Pal, Yu Jun Li et al.
The Oncologist
Cancer Immunotherapy and Biomarkers
article

Blood Cell Count Ratios Predict Immune-related Adverse Events in Metastatic Renal Cell Carcinoma Treated With First-Line Immune Checkpoint Inhibitors

Miguel Zugman, Tanya Dorff, Sumanta Kumar Pal, Yu Jun Li, Regina Barragán-Carrillo, Daniela V. Castro, Hedyeh Ebrahimi, Nazlı Dizman, Salvador Jaime‐Casas, Koral U. Shah, Kaela Makins, Jadon Cooper Fann, George Zhang, Rahul Winayak, Ali Moradi, Joann Hsu, Benjamin Mercier, Vitor Abreu De Goes, Alexander Chehrazi-Raffle, Xiaochen Li, Nicholas J Salgia, Abhishek Tripathi
article en

Abstract

Abstract Background First-line ICI-based therapies are commonplace in mRCC and frequency of irAEs is high. Although prognostication based on irAEs has been demonstrated, prediction of irAE occurrence in mRCC remains a challenge. Early identification of high-risk patients would enable personalized monitoring, earlier detection of irAEs, and more proactive toxicity management. We investigated the role of baseline blood cell count ratios to predict grade ≥2 irAEs with first-line ICI-based therapies in mRCC. Patients and Methods We used the City of Hope national database to retrospectively identify mRCC patients treated with first-line ICI-based therapies from September 2015 to September 2025. Baseline patient demographics and first-line ICI-based regimen were collected. We stratified baseline blood cell ratios: neutrophil-to-eosinophil ratio (NER), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and systemic immune inflammation index (SII) using recursive partitioning and evaluated their association with occurrence of grade ≥2 irAEs. Results A total of 198 patients with mRCC were treated with first-line ICI-based therapy, of which 5 were excluded due to insufficient data. Of the 193 evaluable patients, the median age was 64, 100 patients (51.8%) received ICI-ICI and 93 patients (48.2%) received ICI-TKI. Grade ≥2 irAEs were observed in 57 patients (29.5%) and the most common was ALT/AST elevations in 18 patients (9.3%). All baseline blood cell ratios predicted occurrence of grade ≥2 irAEs in separate multivariable logistic regression analyses for each marker, with SII and PLR emerging as subgroup-specific risk factors in the ICI-ICI and ICI-TKI cohorts, respectively. Conclusion Our findings support a novel role for these baseline blood cell ratios as factors associated with grade ≥2 irAEs in mRCC. These findings are hypothesis-generating and warrant prospective validation in larger patient populations.

The Oncologist
Roswell Park Comprehensive Cancer Center (US), Beth Israel Deaconess Medical Center (US), The University of Texas MD Anderson Cancer Center (US), City of Hope (US), Instituto Nacional de Cancerología (MX)
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon